Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by Oden6570on Dec 02, 2024 5:46am

Roger Clearly States Partner and or license deals for HSV1

Nice reminder of other developments that make your TLT shares undervalued at this time. We may see such a deal as above prior to Phase 2 Trial completion.  Theralase Technologies Announces ...more  
160
Post by Dumbeldorfwhiteon Dec 01, 2024 10:36pm

Can’t wait to be on the call with you guys!

Who's excited to join ole Dumby on the call and how red is the sp going tomorrow?
78
Comment by Dumbeldorfwhiteon Dec 01, 2024 10:28pm

RE:RE:RE:Pioneering is never easy...

Hahahaha post of the year, yeah they ve only been trying to get BTD for 2 years now. Progressing well!
39
Discussion
Comment by Dumbeldorfwhiteon Dec 01, 2024 10:26pm

RE:RE:RE:Pioneering is never easy...

We ve already been over this 11/75 patients had severe adverse reactions to the instillation process. Well above what n803 experienced with many more instillations. I suspect this is the hold up with ...more  
63
Discussion
Comment by lesflicson Dec 01, 2024 10:23pm

RE:RE:RE:RE:Pioneering is never easy...

https://stockhouse.com/news/press-releases/2024/11/27/theralase-r-release-s-3q2024-financial-statements
77
Discussion
Comment by Alamir1111on Dec 01, 2024 8:43pm

RE:RE:RE:Pioneering is never easy...

I don't see much endorsment mention from  .Dr Black
48
Discussion
Comment by McBullishon Dec 01, 2024 8:15pm

RE:RE:RE:Pioneering is never easy...

Is there a shared link or dial in for the call that's been released yet? I need to sign up for corporate communications. TIA
84
Discussion
Comment by BlueFrankyon Dec 01, 2024 5:25pm

RE:RE:RE:Pioneering is never easy...

Eoganacht... You should be considered in some senior PR capacity for this company  You literally bring my blood pressure down every time I read your posts, both rich and objective! As always ...more  
151
Discussion
Comment by Eoganachton Dec 01, 2024 2:55pm

RE:RE:Pioneering is never easy...

Merck's Keytruda, as an NMIBC treatment, has already been far outdone by the FDA approved Adstiladrin, both in terms of efficacy and safety. This is what Dr. Peter Black (principle investigator of ...more  
279
Discussion
Comment by Oilminerdeluxeon Dec 01, 2024 2:30pm

RE:RE:Pioneering is never easy...

Maybe Roger is in a good mood next week and says nice things on the CC. You never know what might transpire.
80
Discussion
Comment by DeathXray33on Dec 01, 2024 2:08pm

RE:Pioneering is never easy...

It's beautiful here. ;-) --- "The Erwin Center in Austin UT-Austin will expand its medical facilities by partnering with MD Anderson Cancer Center to create a new $2.5 billion cancer ...more  
129
Discussion
Comment by Legit62on Dec 01, 2024 12:43pm

RE:RE:RE:Pioneering is never easy...

Totally agree Rollthedice10
72
Discussion
Comment by rollthedice10on Dec 01, 2024 12:04pm

RE:RE:Pioneering is never easy...

Yes it looks like things are well in hand and progressing. TLT is obviously known to FDA and is actively working with them. Another poster suggests writing JFK jr etc about TLT. I don't think that ...more  
206
Discussion
Comment by Maxcitracon Dec 01, 2024 9:32am

RE:Pioneering is never easy...

OCT 7,2024 Theralase update. Theralase wrote: Theralase is actively seeking partnering/licensing opportunities. Wildbird wrote: TLT-Ruvidar with 43.6%CR is 130% more potent than Keytruda at 450 days ...more  
202
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250